JP7725185B2 - 抗ｔｒｅｍ２抗体及びその使用方法 - Google Patents

抗ｔｒｅｍ２抗体及びその使用方法

Info

Publication number
JP7725185B2
JP7725185B2 JP2018517785A JP2018517785A JP7725185B2 JP 7725185 B2 JP7725185 B2 JP 7725185B2 JP 2018517785 A JP2018517785 A JP 2018517785A JP 2018517785 A JP2018517785 A JP 2018517785A JP 7725185 B2 JP7725185 B2 JP 7725185B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
trem2
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018517785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537956A (ja
JP2018537956A5 (enExample
Inventor
ティナ シュワーブ，
フランチェスカ アヴォガドリ－コナーズ，
ヘレン ラム，
イラーリア タッシ，
スンジュ リー，
アーノン ローゼンタール，
Original Assignee
アレクトル エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクトル エルエルシー filed Critical アレクトル エルエルシー
Publication of JP2018537956A publication Critical patent/JP2018537956A/ja
Publication of JP2018537956A5 publication Critical patent/JP2018537956A5/ja
Priority to JP2023060952A priority Critical patent/JP2023093528A/ja
Application granted granted Critical
Publication of JP7725185B2 publication Critical patent/JP7725185B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018517785A 2015-10-06 2016-10-06 抗ｔｒｅｍ２抗体及びその使用方法 Active JP7725185B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023060952A JP2023093528A (ja) 2015-10-06 2023-04-04 抗ｔｒｅｍ２抗体及びその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562238044P 2015-10-06 2015-10-06
US62/238,044 2015-10-06
US201662369666P 2016-08-01 2016-08-01
US62/369,666 2016-08-01
PCT/US2016/055828 WO2017062672A2 (en) 2015-10-06 2016-10-06 Anti-trem2 antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023060952A Division JP2023093528A (ja) 2015-10-06 2023-04-04 抗ｔｒｅｍ２抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2018537956A JP2018537956A (ja) 2018-12-27
JP2018537956A5 JP2018537956A5 (enExample) 2019-11-21
JP7725185B2 true JP7725185B2 (ja) 2025-08-19

Family

ID=57178515

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018517785A Active JP7725185B2 (ja) 2015-10-06 2016-10-06 抗ｔｒｅｍ２抗体及びその使用方法
JP2023060952A Pending JP2023093528A (ja) 2015-10-06 2023-04-04 抗ｔｒｅｍ２抗体及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023060952A Pending JP2023093528A (ja) 2015-10-06 2023-04-04 抗ｔｒｅｍ２抗体及びその使用方法

Country Status (9)

Country Link
US (2) US20190330335A1 (enExample)
EP (1) EP3359569A2 (enExample)
JP (2) JP7725185B2 (enExample)
KR (1) KR20180068999A (enExample)
CN (2) CN108738323B (enExample)
AU (2) AU2016334051B2 (enExample)
CA (1) CA2997960A1 (enExample)
SG (1) SG10201912150TA (enExample)
WO (1) WO2017062672A2 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6674888B2 (ja) 2013-03-13 2020-04-01 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
SG11201700901SA (en) 2014-08-08 2017-03-30 Alector Llc Anti-trem2 antibodies and methods of use thereof
CN106999585A (zh) 2014-09-28 2017-08-01 加利福尼亚大学董事会 对刺激性和非刺激性骨髓细胞的调节
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
CN109219615B (zh) 2016-05-02 2022-12-09 普罗塞纳生物科学有限公司 识别tau的抗体
EP3452509A1 (en) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
PL3452507T3 (pl) 2016-05-02 2023-01-09 Prothena Biosciences Limited Immunoterapia tau
JP2019531332A (ja) * 2016-07-22 2019-10-31 ドイチェス ツェントルム フュール ノイロデゲネラティフェ アークランクンゲン エー．ファウ．（デーツェットエンエー） Ｔｒｅｍ２切断モジュレーター及びその使用
US12138069B2 (en) * 2016-12-13 2024-11-12 Akili Interactive Labs, Inc. Platform for identification of biomarkers using navigation tasks and treatments using navigation tasks
KR20190134997A (ko) 2017-02-17 2019-12-05 데날리 테라퓨틱스 인크. 항-tau 항체 및 이의 사용 방법
AU2018250695A1 (en) * 2017-04-14 2019-11-07 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
EP4548927A3 (en) * 2017-06-21 2025-07-23 The University of North Carolina at Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells
WO2019018828A1 (en) * 2017-07-20 2019-01-24 Cytomx Therapeutics, Inc. METHODS OF QUALITATIVE AND / OR QUANTITATIVE ANALYSIS OF ACTIVATABLE ANTIBODY PROPERTIES AND USES THEREOF
HRP20230675T1 (hr) 2017-08-03 2023-09-29 Alector Llc Anti-trem2 protutijela i postupci njihove uporabe
CA3075285A1 (en) * 2017-09-14 2019-03-21 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
TWI750419B (zh) * 2017-10-16 2021-12-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
CN111712258B (zh) * 2017-12-12 2024-03-15 开拓免疫医疗公司 抗trem2抗体和相关方法
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
WO2019222104A1 (en) * 2018-05-18 2019-11-21 Macrogenics, Inc. Optimized gp41-binding molecules and uses thereof
CN110790837A (zh) * 2018-08-02 2020-02-14 上海君实生物医药科技股份有限公司 抗btla抗体
CN113164572A (zh) * 2018-09-11 2021-07-23 华盛顿大学 抗trem-2激动剂抗体
US12422440B2 (en) 2018-10-05 2025-09-23 Seattle Children's Hospital Newborn screening for primary immunodeficiencies, cystinosis, and Wilson disease
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
CA3115680A1 (en) * 2018-10-23 2020-04-30 Magenta Therapeutics, Inc. Fc silenced antibody drug conjugates (adcs) and uses thereof
KR102156165B1 (ko) * 2018-10-29 2020-09-15 재단법인대구경북과학기술원 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
US20230132366A9 (en) * 2018-11-26 2023-04-27 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
EP3898691A4 (en) * 2018-12-10 2022-09-14 Mor Research Applications TREM2 ANTIBODIES AND THEIR USES
KR20210104079A (ko) * 2018-12-11 2021-08-24 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 항-trem2 항체를 사용하는 방법
JP7681316B2 (ja) * 2019-02-08 2025-05-22 プロセナ バイオサイエンシーズ リミテッド タウを認識する抗体
AU2020226754A1 (en) * 2019-02-20 2021-09-16 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
CA3129331A1 (en) * 2019-02-28 2020-09-03 The Rockefeller University Apoe genotyping in cancer prognostics and treatment
AU2020231366A1 (en) 2019-03-03 2021-08-12 Prothena Biosciences Limited Antibodies recognizing tau
CN110320368A (zh) * 2019-05-30 2019-10-11 广州医科大学附属第一医院（广州呼吸中心） 基于trem2的诊断试剂盒及其在帕金森病诊断产品上的应用
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
PH12022551228A1 (en) * 2019-11-22 2023-06-14 Lilly Co Eli Trem2 antibodies and uses thereof
US20230024528A1 (en) * 2019-12-05 2023-01-26 Alector Llc Methods of use of anti-trem2 antibodies
WO2021119397A1 (en) 2019-12-13 2021-06-17 Rgenix, Inc. Metal salts and uses thereof
TWI890727B (zh) * 2020-01-13 2025-07-21 美商戴納立製藥公司 抗trem2 抗體及其使用方法
CN115279790A (zh) 2020-01-13 2022-11-01 戴纳立制药公司 抗trem2抗体和其使用方法
EP4110814A1 (en) * 2020-02-24 2023-01-04 Alector LLC Methods of use of anti-trem2 antibodies
US11940448B2 (en) 2020-03-31 2024-03-26 Seattle Children's Hospital Proteomic screening for lysosomal storage diseases
IL296992A (en) * 2020-04-03 2022-12-01 Alector Llc Methods of use of anti-trem2 antibodies
MX2022013311A (es) * 2020-04-22 2022-11-14 Akeso Biopharma Inc Anticuerpo biespecifico anti-cd73-anti-pd-1 y uso del mismo.
FI4172199T3 (fi) * 2020-06-26 2025-08-12 Bioarctic Ab Alfa-synukleiinin protofibrilliin sitoutuvat vasta-aineet
IL300327A (en) * 2020-08-05 2023-04-01 Vigil Neuroscience Inc Treatment of diseases associated with colony-stimulating factor receptor 1 dysfunction using TREM2 agonists
CN111944050B (zh) * 2020-08-19 2022-05-13 苏州普乐康医药科技有限公司 一种抗b7-h3抗体及其应用
US20240003918A1 (en) 2020-11-30 2024-01-04 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease
MX2023006397A (es) * 2020-12-04 2023-08-11 Vigil Neuroscience Inc Tratamiento de enfermedades relacionadas con disfunción del transportador 1 del casete de unión a atp utilizando agonistas trem2.
EP4281112A4 (en) * 2021-01-21 2025-01-15 Twist Bioscience Corporation METHODS AND COMPOSITIONS RELATING TO ADENOSINE RECEPTORS
CN112979795B (zh) * 2021-02-26 2022-07-08 深圳市亚辉龙生物科技股份有限公司 抗体组合产品及其在新冠肺炎检测中应用
EP4308586A1 (en) * 2021-03-19 2024-01-24 BicycleTX Limited Bicyclic peptide ligands specific for trem2
CN117396510A (zh) 2021-05-14 2024-01-12 基因泰克公司 Trem2的激动剂
EP4351618A4 (en) * 2021-05-19 2025-09-24 Signablok Inc TREM-2/DAP-12 INHIBITORS FOR TREATING LUNG DISEASES AND INJURIES AND COMBINATIONS THEREOF
CN118302445A (zh) * 2021-08-20 2024-07-05 塔斯里夫制药有限责任公司 抗cd155抗体和抗原结合片段及其使用方法
WO2023039450A2 (en) * 2021-09-07 2023-03-16 Duke University Compositions and methods for treatment of retinal degeneration
JP2024544552A (ja) * 2021-11-09 2024-12-03 ビジル・ニューロサイエンス・インコーポレイテッド ミエロイド細胞に発現するトリガー受容体２アゴニストとしてのヘテロ環化合物
CA3242959A1 (en) 2021-12-17 2025-02-26 Denali Therapeutics Inc POLYPEPTIDE ENGINEERING, LIBRARIES AND ENGINEERED POLYPEPTIDES FOR CD98 HEAVY CHAIN LINK AND TRANSFERRINE RECEIVER
US20230279130A1 (en) * 2022-01-14 2023-09-07 Qilu Puget Sound Biotherapeutics Corporation Anti-ccr8 antibodies
AU2023225020A1 (en) 2022-02-23 2024-09-12 Alector Llc Methods of use of anti-trem2 antibodies
EP4499695A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
US20250215077A1 (en) 2022-03-28 2025-07-03 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
US20250289879A1 (en) * 2022-04-29 2025-09-18 The Children's Medical Center Corporation Therapeutic modulation of genes in myeloid lineage cells and uses thereof in ophthalmology
JP2025529287A (ja) 2022-09-06 2025-09-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル マルファン症候群の処置のためのｔｒｅｍ－２アゴニスト
WO2024182318A2 (en) * 2023-02-28 2024-09-06 Kodiak Sciences Inc. Antibodies to htra1 and conjugates thereof
WO2024226569A1 (en) * 2023-04-24 2024-10-31 The Research Foundation For The State University Of New York Immunogenicity screening method
WO2024253424A1 (ko) * 2023-06-09 2024-12-12 재단법인대구경북과학기술원 인간 trem2 단백질에 특이적으로 결합하는 인간화 항체 및 이의 용도
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025046298A2 (en) 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use
CN117964761B (zh) * 2023-12-21 2025-04-01 华润生物医药有限公司 抗trem2抗体及其用途
WO2025194147A1 (en) * 2024-03-15 2025-09-18 The Children's Medical Center Corporation Therapeutic modulation of trem2 and uses thereof in retinal degeneration

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030165875A1 (en) 2001-03-20 2003-09-04 Marco Colonna Novel receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
JP2004073182A (ja) 2002-05-24 2004-03-11 Takeda Chem Ind Ltd インスリン抵抗性改善剤
JP2010540660A (ja) 2007-10-05 2010-12-24 ユニバーシティ オブ メリーランド，ボルチモア 哺乳類内の赤血球生成を刺激する新規の組成物および方法
JP2011246494A (ja) 2002-12-23 2011-12-08 Schering Corp 哺乳動物サイトカインの用途；関連試薬
JP2017523814A (ja) 2014-08-08 2017-08-24 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
JP4460155B2 (ja) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP2003512821A (ja) 1999-10-04 2003-04-08 メディカゴ インコーポレイテッド 外来性遺伝子の転写調節方法
JP2006504971A (ja) 2002-11-01 2006-02-09 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト マトリックス支援レーザー脱離イオン化−飛行時間型質量分析によるタンパク質アイソフォームの定量的解析
KR20070107687A (ko) 2004-12-31 2007-11-07 제넨테크, 인크. Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
DK2359834T5 (en) 2006-03-15 2017-02-06 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
CA2697193C (en) 2007-09-14 2017-06-06 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
JP6184695B2 (ja) * 2009-12-04 2017-08-23 ジェネンテック， インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
WO2012009568A2 (en) 2010-07-16 2012-01-19 Adimab, Llc Antibody libraries
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030165875A1 (en) 2001-03-20 2003-09-04 Marco Colonna Novel receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
JP2004073182A (ja) 2002-05-24 2004-03-11 Takeda Chem Ind Ltd インスリン抵抗性改善剤
JP2011246494A (ja) 2002-12-23 2011-12-08 Schering Corp 哺乳動物サイトカインの用途；関連試薬
JP2010540660A (ja) 2007-10-05 2010-12-24 ユニバーシティ オブ メリーランド，ボルチモア 哺乳類内の赤血球生成を刺激する新規の組成物および方法
JP2017523814A (ja) 2014-08-08 2017-08-24 アレクトル エルエルシー 抗ｔｒｅｍ２抗体及びその使用方法

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Alzheimer's Research & Therapy, 2013年7月8日,, Vol. 5, 30
Cell, 2015年, Vol. 160, pp. 1061-1071
DATASHEET: Anti-TREM-2 Antibody, clone 78, ONLINE CATALOGUE MERCK, 2016年, https://www.merckmillipore.com/DE/en/product/Anti-TREM-2-Antibody%2C-clone-78,MM_NF-MABN755
European Journal of Neuroscience, 2004年, Vol. 20, pp. 2617-2628
Invest. Ophthalmol. Vis. Sci., 2013年, Vol.54(5), pp. 3451-3462
Journal of Bone and Mineral Research, 2006年, Vol. 21(2), pp. 237-245
Journal of Experimental Medicine, 2001年, Vol. 194(8), pp. 1111-1122
Mol. Neurobiol., 2013年, Vol. 48(1), pp. 180-185
Science Signaling, 2010年05月18日, Vol. 3, No. 122, ra38

Also Published As

Publication number Publication date
CN108738323A (zh) 2018-11-02
WO2017062672A2 (en) 2017-04-13
CN108738323B (zh) 2023-05-26
KR20180068999A (ko) 2018-06-22
AU2016334051B2 (en) 2023-10-26
US20190330335A1 (en) 2019-10-31
JP2023093528A (ja) 2023-07-04
AU2016334051A1 (en) 2018-04-12
CA2997960A1 (en) 2017-04-13
AU2024200443A1 (en) 2024-04-04
EP3359569A2 (en) 2018-08-15
SG10201912150TA (en) 2020-02-27
WO2017062672A3 (en) 2017-05-26
US20230295297A1 (en) 2023-09-21
CN117069841A (zh) 2023-11-17
JP2018537956A (ja) 2018-12-27

Similar Documents

Publication Publication Date Title
US20230295297A1 (en) Anti-trem2 antibodies and methods of use thereof
JP7480197B2 (ja) 抗ｔｒｅｍ１抗体及びその使用方法
JP7730936B2 (ja) 抗ｔｒｅｍ２抗体及びその使用方法
CN108137702B (zh) 抗siglec-7抗体及其使用方法
HK1260289B (en) Anti-trem2 antibodies and methods of use thereof
HK1260289A1 (en) Anti-trem2 antibodies and methods of use thereof
HK1243006B (en) Anti-trem2 antibodies and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210907

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220819

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221206

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230404

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20230418

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230418

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250314

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250806

R150 Certificate of patent or registration of utility model

Ref document number: 7725185

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150